Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.

Journal of inherited metabolic disease - 1 Oct 2010

Spiekerkoetter Ute, Bastin Jean, Gillingham Melanie, Morris Andrew, Wijburg Frits, Wilcken Bridget

Abstract excerpt

Treatment recommendations in mitochondrial fatty acid oxidation (FAO) defects are diverse. With implementation of newborn screening and identification of asymptomatic patients, it is necessary to define whom to treat and how strictly. We here discuss critical questions that are currently under debate. For some asymptomatic long-chain defects, long-chain fat restriction plays a minor role, and a normal diet may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Energy Metabolism
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acids

Share to Lipid Metabolism, Inborn Errors

Share to Mitochondria

Share to Mitochondrial Diseases

Share to Oxidation-Reduction

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 20830526
DOI: 10.1007/s10545-010-9188-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.PMID 20830526Read ↗

Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.Semantic proximity Read ↗

Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.Semantic proximity Read ↗

Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.Semantic proximity Read ↗

Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency.Semantic proximity Read ↗

VLCAD deficiency: Follow-up and outcome of patients diagnosed through newborn screening in Victoria.Semantic proximity Read ↗

Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.Semantic proximity Read ↗

Fatty acid oxidation disorders: outcome and long-term prognosis.Semantic proximity Read ↗

Mitochondrial myopathies: developments in treatment.Semantic proximity Read ↗

Observations regarding retinopathy in mitochondrial trifunctional protein deficiencies.Semantic proximity Read ↗

Pharmacogenomic considerations in the treatment of the pediatric cardiomyopathy called Barth syndrome.Semantic proximity Read ↗

Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches.Semantic proximity Read ↗

Investigating mitochondrial impairment as a mechanism of statin-induced muscle toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.